Literature DB >> 15577913

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Ryan T Phan1, Riccardo Dalla-Favera.   

Abstract

The human proto-oncogene BCL6 encodes a BTB/POZ-zinc-finger transcriptional repressor that is necessary for germinal-centre formation and is implicated in the pathogenesis of B-cell lymphoma. The precise function of BCL6 in germinal-centre development and lymphomagenesis is unclear because very few direct BCL6 target genes have been identified. Here we report that BCL6 suppresses the expression of the p53 (also known as tp53) tumour suppressor gene and modulates DNA damage-induced apoptotic responses in germinal-centre B cells. BCL6 represses p53 transcription by binding two specific DNA sites within the p53 promoter region and, accordingly, p53 expression is absent in germinal-centre B cells where BCL6 is highly expressed. Suppression of BCL6 expression via specific short interfering RNA leads to increased levels of p53 messenger RNA and protein both under basal conditions and in response to DNA damage. Most notably, constitutive expression of BCL6 protects B cell lines from apoptosis induced by DNA damage. These results suggest that an important function of BCL6 is to allow germinal-centre B cells to tolerate the physiological DNA breaks required for immunoglobulin class switch recombination and somatic hypermutation without inducing a p53-dependent apoptotic response. These findings also imply that deregulated BCL6 expression contributes to lymphomagenesis in part by functional inactivation of p53.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577913     DOI: 10.1038/nature03147

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  263 in total

Review 1.  Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Authors:  Maribel Cotto; Fernando Cabanillas; Maribel Tirado; María V García; Eileen Pacheco
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Authors:  Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

3.  A unique role for ITK in survival of invariant NKT cells associated with the p53-dependent pathway in mice.

Authors:  Qian Qi; Weishan Huang; Yuting Bai; Gabriel Balmus; Robert S Weiss; Avery August
Journal:  J Immunol       Date:  2012-03-07       Impact factor: 5.422

4.  A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

Authors:  Wyndham H Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; Dan Jones; Kieron Dunleavy; George Canellos; Andrew D Zelenetz; Bruce D Cheson; Eric D Hsi
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

5.  Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis.

Authors:  María Rodríguez Martínez; Alberto Corradin; Ulf Klein; Mariano Javier Álvarez; Gianna M Toffolo; Barbara di Camillo; Andrea Califano; Gustavo A Stolovitzky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 6.  POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.

Authors:  Sung-Uk Lee; Takahiro Maeda
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

Review 7.  Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology.

Authors:  Jane N Winter
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

8.  BCL6 canalizes Notch-dependent transcription, excluding Mastermind-like1 from selected target genes during left-right patterning.

Authors:  Daisuke Sakano; Akiko Kato; Nisarg Parikh; Kelly McKnight; Doris Terry; Branko Stefanovic; Yoichi Kato
Journal:  Dev Cell       Date:  2010-03-16       Impact factor: 12.270

9.  Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas.

Authors:  Monica Gostissa; Julia M Bianco; Daniel J Malkin; Jeffery L Kutok; Scott J Rodig; Herbert C Morse; Craig H Bassing; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 10.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.